CAR T cell therapy is driving better cancer treatment outcomes
Link copied to
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses cancer treatment through the use of CAR T cell therapy.
Chimeric grabbed headlines in January 2021, following news it easily achieved its IPO fundraising target of $35m.
Prescient also featured in a recent Stockhead article looking at its choice of three cancer programs for its next-generation CAR T platform.
The group discusses a range of topics, including how both companies began developing CAR T cell therapies, the tumour types being targeted, timescales towards strong revenue, research plans for the year ahead and much more.
So click above to tune in.